Experience of CGM (Continuous Glucose Monitoring) for children and adolescents in a paedriatric diabetes unit
Resumen: Abstract [ATTD19-0011]
Objective: Estimate the use of CGM in a Pediatric Diabetes Unit from a Spanish region. To find out differences between the different CGM systems (included flash type or intermittent) and according to the type of treatment. To analyze the metabolic control, frequency of mild and severe hypoglycaemia among the same patients before and after using CGM and to compare patients with and without CGM.
Methods: Data are collected from September to December 2017, from patients whose diagnosis was between 2003 and 2017. Patients are grouped in age groups (<5; 6–10;> 10) and demographic, metabolic control and treatment variables are collected.
Results: 120 patients collaborated, implying a response of 80%.70% use MDI, of which 48% use CGM, being 89% in the case of patients using CSII. In older than 10 years there is a predilection for intermittent measurement systems, unlike those under 5 years prefer continuous measurement. The use of CGM significantly reduces HbA1c compared to those who do not use them and significantly reduces the number of mild hypoglycaemia, with the disappearance of severe hypoglycaemia in 6 months. 43% of patients reduce the number of glycemias/day significantly after 6 months of use. CGM decreases almost a 5% the HbAc1 value and a 19% the Coefficient of Variation.
Conclusion: There exists an improvement in the metabolic control and the glycemic variability of using CGM. Hypoglycemia is diminished by GCM, to a greater extent by the Integrated sensor-augmented pump system. Adolescents prefer to use intermittent measurement systems, reducing the number of glycemia/d.

Idioma: Inglés
DOI: 10.1089/dia.2019.2525.abstracts
Año: 2019
Publicado en: Diabetes Technology & Therapeutics 21, S1 (2019), A90-A91
ISSN: 1520-9156

Originalmente disponible en: Texto completo de la revista

Factor impacto JCR: 4.392 (2019)
Categ. JCR: ENDOCRINOLOGY & METABOLISM rank: 30 / 143 = 0.21 (2019) - Q1 - T1
Factor impacto SCIMAGO: 1.819 - Endocrinology (Q1) - Medicine (miscellaneous) (Q1) - Medical Laboratory Technology (Q1) - Endocrinology, Diabetes and Metabolism (Q1)

Tipo y forma: Comunicación congreso (Versión definitiva)
Área (Departamento): Área Fund. Análisis Económico (Dpto. Análisis Económico)
Área (Departamento): Área Comerci.Investig.Mercados (Dpto. Direc.Mark.Inves.Mercad.)


Derechos Reservados Derechos reservados por el editor de la revista


Exportado de SIDERAL (2020-10-29-14:06:48)


Visitas y descargas

Este artículo se encuentra en las siguientes colecciones:
Artículos > Artículos por área > Comercialización e Investigación de Mercados
Artículos > Artículos por área > Fundamentos del Análisis Económico



 Registro creado el 2020-10-29, última modificación el 2020-10-29


Versión publicada:
 PDF
Valore este documento:

Rate this document:
1
2
3
 
(Sin ninguna reseña)